Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medterra Daily Relief Pet CBD Tincture is a consumer wellness supplement developed by Medterra for use in dogs and cats. The product features hemp-derived cannabidiol (CBD) isolate, ensuring a THC-free formulation that is standardized to 10mg of CBD per 1mL serving. It is delivered in an organic medium-chain triglyceride (MCT) oil base, which facilitates oral or sublingual absorption. The tincture is intended to support the pet's endocannabinoid system to promote calmness, manage stress-related anxiety, and support joint health and mobility. As a non-pharmaceutical consumer product, it is third-party lab tested and adheres to U.S. Hemp Authority certification standards, offering various flavors like beef and chicken to enhance compliance in domestic animals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Medterra Daily Relief Pet CBD Tincture.